BREZTRI AEROSPHERE

BREZTRI is a single inhaler that contains three medications, making it a convenient maintenance treatment for COPD. These medications include an inhaled corticosteroid (budesonide), an anticholinergic (glycopyrrolate), and a long-acting beta2-adrenergic agonist (formoterol fumarate).

Breztri Aerosphere is an effective treatment for improving lung function and decreasing the frequency of COPD flare-ups. It also lowers the chances of hospitalization or death related to COPD. However, it is important to note that Breztri Aerosphere is not suitable for treating asthma. Additionally, it should not be used as a rescue medication.

Other potential side effects linked to the individual components of BREZTRI AEROSPHERE are hyperglycemia, anxiety, insomnia, headache, palpitations, nausea, hypersensitivity, depression, agitation, restlessness, nervousness, tremor, dizziness, angina pectoris, tachycardia, and cardiac issues.

Breztri Aerosphere is currently only available as a brand-name drug and does not have a generic version. Generic drugs are identical copies of the active drug in a brand-name medication and are typically less expensive.

Symptoms include fatigue, muscle weakness, nausea, vomiting, and low blood pressure.

Breztri Aerosphere gradually opens up airways and relaxes lung muscles, whereas albuterol provides immediate relief but has a shorter duration of action.

In cases of sudden breathlessness, rescue medications are essential for quickly opening airways. However, it’s important to note that Breztri Aerosphere is not intended for use as a rescue medication due to its slower onset of action. If you experience sudden breathlessness, it’s crucial to use your prescribed rescue inhaler, such as albuterol, as directed by your doctor.

Please keep BREZTRI in the sealed foil pouch until you are ready to use it. Dispose of BREZTRI safely in the trash after 3 weeks (for the 28-inhalation canister) or 3 months (for the 120-inhalation canister) from the date you opened the foil pouch.

Approved Use: BREZTRI AEROSPHERE is indicated for the long-term treatment of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis, emphysema, or both, to improve breathing and reduce the frequency of flare-ups. It should be noted that BREZTRI is not intended for immediate relief of sudden breathing difficulties and should not be used as a substitute for a rescue inhaler.

No, weight gain was not observed as a side effect in the clinical trials of Breztri Aerosphere. However, it is important to note that one of the components of Breztri Aerosphere, budesonide, is a corticosteroid drug that can potentially decrease adrenal function. This may result in weight loss rather than weight gain.

If you experience any severe side effects, such as white patches on your tongue or in your mouth, signs of infection like a persistent sore throat or fever, painful or difficult urination, muscle cramps or weakness, increased thirst or urination, bone pain, or changes in your mental or emotional state like nervousness, be sure to inform your doctor immediately.

Breztri Aerosphere may be included in certain Medicare and insurance plans. The most commonly prescribed version of Breztri Aerosphere has a lowest NowPatient Rx Advantage Card price of approximately $627.54, which is 16% lower than the average retail price of $753.03. You can compare this beta agonist / anticholinergic / corticosteroid combination with others.

Conditions that may occur include thrush, pneumonia, immunosuppression, adrenal insufficiency, and sudden breathing problems after inhaling medication.

To ensure a safe transition to BREZTRI AEROSPHERE, patients who are currently taking systemic corticosteroids should gradually reduce their dosage. This can be achieved by decreasing the daily prednisone dose by 2.5 mg per week while using BREZTRI AEROSPHERE.

The most commonly used combination inhalers for COPD that contain long-acting bronchodilators (LABA + LAMA) are Anoro Ellipta (umeclidinium/vilanterol), Stiolto Respimat (tiotropium/olodaterol), and Bevespi Aerosphere (glycopyrrolate/formoterol).

Proair HFA, Ventolin HFA, Proventil HFA, Accuneb, and Proair RespiClick are all types of rescue inhalers that contain albuterol, a short-acting beta-agonist. These inhalers are used to help with urgent breathing problems and can be used about 15 to 30 minutes prior to exercise to prevent exercise-induced symptoms.

BREZTRI has been proven to enhance lung function within 5 minutes of consumption. Individual outcomes may differ. It is important to note that BREZTRI is not intended for immediate relief of breathing difficulties and should not be used as a substitute for a rescue inhaler. Additionally, BREZTRI is not suitable for treating asthma.

No, weight gain was not observed as a side effect in the clinical trials of Breztri Aerosphere. However, it is important to note that one of the components of Breztri Aerosphere, budesonide, is a corticosteroid drug that can potentially decrease adrenal function. This may result in weight loss rather than weight gain.

It is generally recommended to take only one medicine from the ‘cortisones’ category at a time.

To minimize the risk of developing thrush, it is advised to rinse your mouth with water after using BREZTRI and avoid swallowing. This is because BREZTRI may lead to fungal infection in the mouth or throat.

The suggested amount of BREZTRI AEROSPHERE is 320 mcg of budesonide, 18 mcg of glycopyrrolate, and 9.6 mcg of formoterol fumarate. This should be taken as 2 inhalations of BREZTRI AEROSPHERE (160 mcg/9 mcg/4.8 mcg) twice a day, once in the morning and once in the evening, through oral inhalation.

To properly use BREZTRI, it should be taken as 2 inhalations, twice daily. After each inhalation, the patient should rinse their mouth with water without swallowing. It is important to prime the BREZTRI AEROSPHERE to ensure the correct amount of medication in each dose. Each canister of BREZTRI AEROSPHERE contains either 28 or 120 inhalations.

If you experience any unusual symptoms such as worsening shortness of breath, chest pain, increased heart rate, or shakiness after taking an excessive amount of Breztri Aerosphere, it is important to immediately contact your healthcare provider or visit the nearest hospital emergency room.

BREZTRI AEROSPHERE is a medication prescribed for the long-term treatment of chronic obstructive pulmonary disease (COPD), which includes chronic bronchitis, emphysema, or both. It helps improve breathing and reduces the frequency of flare-ups. However, it should not be used for immediate relief during sudden breathing difficulties and should not be used as a substitute for a rescue inhaler.

Other potential side effects linked to the individual components of BREZTRI AEROSPHERE are hyperglycemia, anxiety, insomnia, headache, palpitations, nausea, hypersensitivity, depression, agitation, restlessness, nervousness, tremor, dizziness, angina pectoris, tachycardia, and cardiac issues.

Advair is a widely prescribed inhaler for the ongoing management of COPD. It contains a combination of fluticasone, a corticosteroid, and salmeterol, a long-acting bronchodilator. To effectively control COPD symptoms, Advair is taken twice daily as part of a regular maintenance routine.

If you and your doctor agree that Breztri Aerosphere is safe and effective for you, it is intended for long-term use.

Breztri Aerosphere is a medication that contains three different medicines: budesonide, glycopyrrolate, and formoterol fumarate. These medicines are combined in one inhaler and are delivered as a propelled spray. Budesonide is an inhaled corticosteroid, glycopyrrolate is an anticholinergic, and formoterol fumarate is a long-acting beta2-adrenergic agonist.

If you are taking formoterol and vilanterol together, it is important to be aware that this combination may lead to cardiovascular side effects. These side effects can include an increase in heart rate and blood pressure, as well as irregular heart rhythm. If you have any questions or concerns about this, it is recommended that you speak with your doctor. This is especially important if you have a history of high blood pressure, arrhythmia, or heart disease.

Breztri is an inhaler that combines three different medications: budesonide, glycopyrrolate, and formoterol fumarate. In contrast, Symbicort is an inhaler that combines two of these medications: budesonide and formoterol fumarate.

Symbicort contains budesonide and formoterol fumarate. Breztri contains budesonide, glycopyrrolate, and formoterol fumarate. Both are used for the treatment of COPD. The effectiveness of Symbicort and Breztri for an individual will vary, depending on each persons condition and their response to the treatment.

Breztri improves lung function within 5 minutes of use, but will not relieve sudden breathing problems and should not be used as a rescue inhaler.